BioLineRx (NASDAQ:BLRX) Share Price Passes Above Two Hundred Day Moving Average of $0.81

Shares of BioLineRx Ltd. (NASDAQ:BLRX – Get Rating) crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.81 and traded as high as $1.66. BioLineRx shares last traded at $1.55, with a volume of 663,745 shares trading hands.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on BLRX shares. HC Wainwright restated a “buy” rating on shares of BioLineRx in a report on Wednesday, March 22nd. StockNews.com assumed coverage on shares of BioLineRx in a report on Thursday, May 18th. They set a “sell” rating on the stock.

BioLineRx Price Performance

The stock’s 50-day moving average is $1.12 and its 200 day moving average is $0.81. The stock has a market capitalization of $95.37 million, a PE ratio of -3.10 and a beta of 1.89. The company has a quick ratio of 4.87, a current ratio of 4.87 and a debt-to-equity ratio of 0.17.

BioLineRx (NASDAQ:BLRX – Get Rating) last posted its earnings results on Wednesday, March 22nd. The biotechnology company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.05. As a group, equities analysts predict that BioLineRx Ltd. will post -0.6 earnings per share for the current year.

Institutional Trading of BioLineRx

Large investors have recently added to or reduced their stakes in the business. Armistice Capital LLC bought a new stake in BioLineRx in the third quarter worth approximately $2,587,000. Altium Capital Management LP bought a new stake in BioLineRx in the third quarter worth approximately $3,838,000. Atria Wealth Solutions Inc. bought a new stake in shares of BioLineRx during the 1st quarter worth $178,000. Renaissance Technologies LLC boosted its holdings in shares of BioLineRx by 278.0% during the 4th quarter. Renaissance Technologies LLC now owns 257,900 shares of the biotechnology company’s stock worth $152,000 after buying an additional 189,678 shares during the period. Finally, Envestnet Asset Management Inc. bought a new stake in shares of BioLineRx during the 1st quarter worth $88,000. 18.15% of the stock is owned by institutional investors.

About BioLineRx

(Get Rating)

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors.